Dan Brown, MD, shows case examples demonstrating timing of Y-90 therapy and personalizing therapy to the patient's biology.
Current Therapy for Neuroendocrine Disease: When is Lutetium-177 Peptide Receptor Radionuclide Therapy Indicated?
Because overall survival of patients with metastatic neuroendocrine tumors (NET) is usually longer than other types of metastatic cancers, deciding which treatment can best control the disease over a long period of time without causing long-term side effects that might affect survival or quality of… Read More
In this video, Sean M. Tutton, MD, FSIR discusses the 5 P’s of MSK interventions and the importance of remembering the mnemonic device “Prior Planning Prevents Poor Performance.”
Ablation and stereotactic body radiation therapy (SBRT) are both effective treatments for patients with hepatocellular carcinoma (HCC), especially those in early stages of the disease. Siddharth A. Padia, MD explains what interventional radiologists need to know when deciding between ablation and… Read More
In this video, Matthew Callstrom, MD, PhD discusses the risk of collecting system injury with microwave ablation and how central renal tumors can be effectively treated.
When talking to hospitals and oncologists about the benefits of having a full-time interventional radiology (IR) faculty, it is important to highlight the work related value units (wRVUs) that can be brought in from a clinical prospective, according to a presentation from Sarah White, MD, MS, FSIR… Read More
In this video Peter Littrup, MD discusses a case of renal cryoablation including hydrodissection, cryoprobe placement, and cryoablation monitoring.
Interventional radiologists who are interested in performing Y90 should be aware of clinical red flags including bilirubin trends, potent radiosensitizers, prior biliary intervention, and the presence of ascites, according to a presentation by Ripal Gandhi, MD, FSVM, FSIR at the Symposium on… Read More